Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2025
0mins
Source: NASDAQ.COM
Hims & Hers Health Performance: Hims & Hers stock surged 11.2% after reporting a sales beat with a 111% year-over-year increase, despite an earnings miss of $0.20 per share compared to the expected $0.23. The company forecasts continued growth, projecting sales between $2.3 billion and $2.4 billion for the year.
Impact on Competitors: The positive outlook for Hims & Hers is seen as a competitive threat to larger drugmakers like Eli Lilly and Novo Nordisk, whose stocks fell by 3.2% following the news, indicating concerns about sharing future profits in the GLP-1 market.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 42.88 USD with a low forecast of 29.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
7 Hold
3 Sell
Hold
Current: 30.520
Low
29.00
Averages
42.88
High
85.00
Current: 30.520
Low
29.00
Averages
42.88
High
85.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
